Evolving use of new oral anticoagulants for treatment of venous thromboembolism
Why the study?
Do new oral anticoagulants (NOACs) prevent recurrence and reduce bleeding compared to conventional anticoagulant therapy in patients with venous thromboembolism?
Population
Patients with venous thromboembolism (VTE)
Comparison
New oral anticoagulants including dabigatran… vs Conventional anticoagulant therapy
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support preferring NOACs for VTE; leaves open optimal duration and subgroup-specific outcomes.
Structured PICO
Do new oral anticoagulants (NOACs) prevent recurrence and reduce bleeding compared to conventional anticoagulant therapy in patients with venous thromboembolism?
P
Population
Patients with venous thromboembolism (VTE)
I
Intervention
New oral anticoagulants (NOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban
C
Comparator
Conventional anticoagulant therapy (e.g., warfarin)
O
Outcome
Prevention of VTE recurrence and bleeding
NOACs offer a streamlined, noninferior alternative to conventional anticoagulants for VTE treatment with a lower risk of bleeding.
Cite This Study
Yeh et al. (2014) studied this question.